The Company’s accounting policies for share-based compensation are described in Note 7, “Share-Based Compensation Plan,” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes to these policies during the three and nine months ended September 30, 2026. The disclosures below should be read in conjunction with that note.

During the three and nine months ended September 30, 2026, the Company did not grant stock option awards and no stock option awards were forfeited. As of September 30, 2026, no unrecognized compensation remains for time-based and performance-based stock options as they are fully vested.


	Time Based						Performance Based
	Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value		Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding as of December 31, 2025	4,351,430	$	5.80	8.2	$	101,658	4,426,955	$	5.79	8.3	$	103,445
Granted	—	—					—	—
Exercised	(91,500)	5.53					(97,981)	5.52
Forfeited	—	—					—	—
Expired	—	—					—	—
Outstanding as of March 31, 2026	4,259,930	$	5.80	7.8	$	75,087	4,328,974	$	5.80	7.8	$	76,326
Exercisable as of March 31, 2026	4,259,930	$	5.80	7.8	$	75,087	4,328,974	$	5.80	7.8	$	76,326
Granted	—	—					—	—
Exercised	(86,278)	5.50					(57,603)	5.50
Forfeited	—	—					—	—
Expired	—	—					—	—
Outstanding as of June 30, 2026	4,173,652	$	5.81	7.5	$	102,964	4,271,371	$	5.80	7.5	$	105,406
Exercisable as of June 30, 2026	4,173,652	$	5.81	7.5	$	102,964	4,271,371	$	5.80	7.5	$	105,406
Granted	—	—					—	—
Exercised	(46,500)	5.50					(41,150)	5.50
Forfeited	—	—					—	—
Expired	—	—					—	—
Outstanding as of September 30, 2026	4,127,152	$	5.81	7.2	$	88,885	4,230,221	$	5.81	7.2	$	91,137
Exercisable as of September 30, 2026	4,127,152	$	5.81	7.2	$	88,885	4,230,221	$	5.81	7.2	$	91,137

During the three and nine months ended September 30, 2026, 2,763 and 3,867 RSUs were forfeited, respectively. During the three and nine months ended September 30, 2026, 1,383,937 and 1,383,937 RSUs vested and 1,031,448 and 1,031,448 RSUs were granted, respectively. On September 8, 2026, the Compensation Committee of the Board approved an amendment to the vesting schedule of the RSUs granted in 2025. The first installment, representing one-third of each award, remained scheduled to vest on the first anniversary of the vesting commencement date. The remaining two-thirds of each award, which were previously scheduled to vest in annual installments on the second and third anniversaries of the vesting commencement date, will vest in eight equal quarterly installments beginning three months after the first anniversary of the vesting commencement date. The amendment did not change the number of RSUs, the final vesting date, or the aggregate grant-date fair value of the awards, and did not result in incremental share-based compensation expense. As of September 30, 2026, there were 3,821,132 RSUs outstanding with a weighted-average grant-date fair value of $22.03 per unit and a weighted-average remaining service period of 2.3 years.


	Number of Units	Weighted Average Grant Date Fair Value		Weighted Average Remaining Service Period
Outstanding as of December 31, 2025	4,177,488	$	20.04	2.8
Granted	—	—		—
Vested	—	—		—
Forfeited	—	—		—
Outstanding as of March 31, 2026	4,177,488	$	20.04	2.5
Granted	—	—		—
Vested	—	—		—
Forfeited	(1,104)	20.00		—
Outstanding as of June 30, 2026	4,176,384	$	20.04	2.3
Granted	1,031,448	27.35		—
Vested	(1,383,937)	20.00		—
Forfeited	(2,763)	20.00		—
Outstanding as of September 30, 2026	3,821,132	$	22.03	2.3

During the three and nine months ended September 30, 2026, the Company recognized $7,009 and $20,832 of share-based compensation expense related to RSUs, respectively, which is included in employee compensation and benefits expense in the condensed consolidated statements of income. As of September 30, 2026, unrecognized compensation cost related to unvested RSUs was $84,046, which is expected to be recognized over a weighted-average period of 2.3 years.